enow.com Web Search

  1. Ads

    related to: new drug to stop pah post nasal

Search results

  1. Results from the WOW.Com Content Network
  2. Sitaxentan - Wikipedia

    en.wikipedia.org/wiki/Sitaxentan

    Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH). [1] It was marketed as Thelin by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity. [2]

  3. Selexipag - Wikipedia

    en.wikipedia.org/wiki/Selexipag

    Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). [3] [4] Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. [5]

  4. Iloprost - Wikipedia

    en.wikipedia.org/wiki/Iloprost

    Iloprost, sold under the brand name Ventavis among others, is a medication used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, frostbite, and other conditions in which the blood vessels are constricted and blood cannot flow to the tissues. [4] Iloprost is a prostacyclin mimetic. [1]

  5. Methylscopolamine bromide - Wikipedia

    en.wikipedia.org/wiki/Methylscopolamine_bromide

    Methylscopolamine or methscopolamine, usually provided as the bromide or nitrate salt, is an oral medication used along with other medications to treat peptic ulcers by reducing stomach acid secretion. [1] Proton pump inhibitors and antihistamine medications have made this use obsolete.

  6. Foscarbidopa/foslevodopa - Wikipedia

    en.wikipedia.org/wiki/Foscarbidopa/foslevodopa

    The combination was refused approval by the US Food and Drug Administration (FDA) in 2023. [11] It was approved for medical use in Canada in May 2023, [ 4 ] in Australia in March 2024, [ 1 ] and in the United States in October 2024.

  7. Macitentan - Wikipedia

    en.wikipedia.org/wiki/Macitentan

    Macitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). [5] Macitentan is a dual endothelin receptor antagonist, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ET A and ET B . [ 5 ]

  8. Post-nasal drip - Wikipedia

    en.wikipedia.org/wiki/Post-nasal_drip

    Treatment options depend on the nature of an individual's post-nasal drip and its cause. Antibiotics may be prescribed if the PND is the result of bacterial sinusitis. [ 8 ] In cases where PND is caused by allergic rhinitis or irritant rhinitis, avoidance of allergens or irritating factors such as dander, cigarette smoke, and cleaning supplies ...

  9. Xylometazoline - Wikipedia

    en.wikipedia.org/wiki/Xylometazoline

    The smaller arteries are also constricted and this causes the colour of the nasal epithelium to be visibly paler after dosage. Xylometazoline is an imidazole derivative which is designed to mimic the molecular shape of adrenaline. It binds to α 1 and α 2 adrenergic receptors [11] in the nasal mucosa.

  1. Ads

    related to: new drug to stop pah post nasal